Ayumi Fujimoto1, Fumihiro Ishida2,8, Koji Izutsu3, Satoshi Yamasaki4, Dai Chihara5, Junji Suzumiya1, Tetsuo Mitsui6, Kazuteru Ohashi7, Hideyuki Nakazawa8, Hikaru Kobayashi9, Junya Kanda10, Takahiro Fukuda11, Yoshiko Atsuta12, Ritsuro Suzuki1 (1.Oncology and Hematology, Shimane University Hospital, Izumo, Japan, 2.Biomedical Laboratory Sciences, Shinshu University School of Medicine, Matsumoto, Japan, 3.Hematology, National Cancer Center Hospital, Tokyo, Japan, 4.Hematology and Clinical Research Institute, Kyushu Medical Center, Fukuoka, Japan, 5.Center for Cancer Research National Cancer Institute, Bethesda, MD, USA, 6.Pediatrics, Yamagata University School of Medicine, Yamagata, Japan, 7.Hematology, Komagome Hospital, Tokyo, Japan, 8.Hematology, Shinshu University School of Medicine, Matsumoto, Japan, 9.Hematology, Nagano Red Cross Hospital, Nagano, Japan, 10.Hematology and Oncology, Kyoto University, Kyoto, Japan, 11.Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan, 12.Japanese Data Center for Hematopoietic Cell Transplantation)
Session information
SETP
SETP2 Lymphoid Malignancies
Fri. Oct 11, 2019 3:20 PM - 4:20 PM No.17 (Tokyo International Forum, 4F G407)
Commentator: Kerry Savage (British Columbia Cancer Agency)
Moderator: Motoko Yamaguchi (Mie University Graduate School of Medicine)
Hirotaka Miyashita1, Kazuki Taoka1, Ayako Kume2, Kazuhiro Toyama1, Aya Ushiku2, Yosuke Masamoto1, Tetsuo Ushiku2, Mineo Kurokawa1 (1.Hematology Oncology, The University of Tokyo, Tokyo, Japan, 2.Department of Pathology, The University of Tokyo Hospital, Tokyo, Japan)